FDA Investigator Patricia A Cochran

Patricia A Cochran has conducted inspections on 23 sites in 2 countries as of 14 Jul 2003. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
23
Last Inspection Date:
14 Jul 2003
Investigator Role:
FDA Investigation Participant
Redica ID:
100000648
Countries of Inspections:
United States of America, Canada
FDA Investigators that have inspected at least one site in common with Patricia A Cochran:
Amanda L Baskin, Andrace L Deyampert, Andre S Raw, Andrea D Swingle, Andrew H Paeng, Angel S Johnson, Ann L Demarco, Azza Talaat, Bei Y He, Benjamin J Smith, Bernard P Heidt, Brian D Garthwaite, Byungja E Marciante, Carolyn E Barney, Catherine J Laufmann, CDR Sean T Creighton, Charles I Ann, Charles L Zhou, Charles M Edwards, Charles M Spyr, Christopher T Middendorf, Constantin Y Philopoulos, Corrine M Carter, Darren S Morgan, David A Paterson, David L Duncan, Dawn M Braswell, Debara R Reese, Debara Reese, Denise L Burosh, Dennis E Guilfoyle, PhD, Dina A Tallman, Donald C Obenhuber, PhD, Dr. Abhijit Raha, PhD, Dr. Roy A Blay, PhD, Emest F Bizjak, Emily J Orban, Erin D Mccaffery, Etty Feller, Jacqueline Mdiaz Albertini, James L Finn, Jean Blackston Hill, Jeffrey A Sommers, Jeffrey D Meng, Jennifer A Kemp, Jorge F Christian, Joris Vanloco, Joseph A Piechocki, Joseph R Strelnik, Karen M Montgomery (KMM), Kevin Obrien, L'oreal F Walker, Larry K Austin, Lauren Iacono Connors, PhD, Leigh Anne Myers, Lisa M Bellows, Luella J Rossi, Lynda L Lanning, Mei Chiung Huang (Jo), Meisha R Sampson, Meisha Waters, Melina Lrodriguez Upton, Mercy Oyugi, Michael Shanks, MS, Michael Y Philopoulos, Michele Gottshall, Michele L Forster, PhD, Montgomery Montgomery, Karen M, Muna Algharibeh, Myra K Casey, Nailing Zhang, Neali H Lucas, Omotunde O Osunsanmi, Patricia A Birham, Patricia H Dlugosz, Patrick B Cummings, Patsy J Domingo, Prabhu P Raju, Qiao Y Bobo, Rafeeq A Habeeb, Ralph A Erickson, Raymond T Oji, Rebecca E Dombrowski, Regina T Brown, Robert D Tollefsen, Robert J Ham, Robert M Barbosa, Sandra A Boyd, Sanket N Patel, Sargum C Sood, Shannon A Gregory, Sidney B Priesmeyer, Susan F Laska, MS, Susan O Oladeji, Susan P Bruederle, Suyang Qin, Talmane J Fisher, Thomas J Arista, Thuy T Nguyen, LCDR, Timothy C Schell, Tina M Pawlowski, Tracey L Siebesma, Tracy K Li, Truong Xuan Nguyen (Andy), Wayne E Seifert, William D Tingley, Yangmin Ning, Yumi J Hiramine

Patricia A Cochran's Documents

Publish Date Document Type Title
June, 2001 EIR BWXT Medical Ltd. - EIR, 2001-06-15
November, 2000 EIR Prystowsky, Eric N., Dr. - EIR, 2000-11-17
January, 2002 FDA 483 Response Eli Lilly and Company - Form 483R, 2002-02-06
July, 2002 FDA 483 Paras Harshawat, M.D. - Form 483, 2002-07-12
June, 2002 FDA 483 Response Labcorp Drug Development Inc. - Form 483R, 2002-06-14
January, 2003 FDA 483 Covance Bioanalytical Services, LLC - Form 483, 2003-01-03
January, 2002 FDA 483 Eli Lilly and Company - Form 483, 2002-01-11
August, 2000 FDA 483 Lilly, Eli Co. Tippecanoe Lab - Form 483, 2000-08-11
August, 2003 FDA 483 Scholnik, Aaron MD - Form 483, 2003-08-18
June, 2002 EIR Labcorp Drug Development Inc. - EIR, 2002-03-22
May, 2002 EIR Eli Lilly and Company - EIR, 2002-05-30
January, 2002 FDA 483 Response Eli Lilly and Company - Form 483R, 2002-01-25
August, 2000 EIR Evonik Corporation - EIR, 2000-08-11
April, 2001 FDA 483 Eli Lilly and Company - Form 483, 2001-04-05
June, 2001 FDA 483 MDS NORDION - Form 483, 2001-06-15
June, 2000 EIR Gary A. Cohen - EIR, 2000-06-22
May, 2002 FDA 483 Eli Lilly and Company - Form 483, 2002-05-30
January, 2002 EIR Eli Lilly and Company - EIR, 2002-01-24
October, 2000 FDA 483 Response Marek Gawel, M.D. - Form 483R, 2000-10-24
November, 2001 FDA 483 Eli Lilly and Company - Form 483, 2001-11-14
June, 2000 EIR Cohen, Gary W Md - EIR, 2000-06-22
August, 2000 FDA 483 Response Evonik Corporation - Form 483R, 2000-08-24
February, 2001 FDA 483 Eli Lilly and Company - Form 483, 2001-02-23
February, 2001 FDA 483 Response Eli Lilly and Company - Form 483R, 2001-03-08
October, 2000 FDA 483 Response Jaques Meloche, M.D. - Form 483R, 2000-12-29
January, 2002 FDA 483 Eli Lilly and Company - Form 483, 2002-01-24
August, 2000 EIR Labcorp Drug Development Inc. - EIR, 2000-08-30
October, 2000 EIR Marek Gawel, M.D. - EIR, 2000-10-24
June, 2002 FDA 483 Labcorp Drug Development Inc. - Form 483, 2002-06-04
August, 2000 FDA 483 Labcorp Drug Development Inc. - Form 483, 2000-08-30
January, 2003 EIR Covance Bioanalytical Services, LLC - EIR, 2003-01-03
January, 2002 EIR Eli Lilly and Company - EIR, 2002-01-11
June, 2000 FDA 483 Cohen, Gary W Md - Form 483, 2000-06-22
June, 2002 FDA 483 Labcorp Drug Development Inc. - Form 483, 2002-03-22
April, 2003 FDA 483 Priscilla Laboratories, Inc. - Form 483, 2003-04-25
June, 2002 EIR Labcorp Drug Development Inc. - EIR, 2002-05-30
October, 2000 EIR Jaques Meloche, M.D. - EIR, 2000-10-26
August, 2003 EIR Scholnik, Aaron MD - EIR, 2003-08-18
November, 2001 FDA 483 Response Eli Lilly and Company - Form 483R, 2001-12-03
May, 2002 FDA 483 Response Eli Lilly and Company - Form 483R, 2002-05-30
June, 2002 EIR Cook Incorporated - EIR, 2002-06-25
June, 2002 FDA 483 Response Labcorp Drug Development Inc. - Form 483R, 2002-06-14
May, 2002 FDA 483 Eli Lilly & Company - Form 483, 2002-05-30
January, 2002 EIR Eli Lilly and Company - EIR, 2002-01-14

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more